Castle Biosciences, Inc.CSTLNASDAQ

Revenue (LTM)

$344M

+3.7% YoY

Net Income (LTM)

$-24M

-232.4% YoY

Free Cash Flow

$28M

Revenue CAGR (5Y)

+40.6%

Marginsdeclining

FCF$0.0B

Now unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	94	137↑45.7%	220↑60.4%	332↑51.1%	344↑3.7%
Gross Profit	78	105↑34.2%	175↑66.4%	272↑55.5%	236↓13.1%
Operating Income	-40	-73↓81.8%	-68↑6.7%	9↑112.8%	-43↓593.8%
Net Income	-31	-67↓114.6%	-57↑14.4%	18↑131.7%	-24↓232.4%
EBITDA	-37	-58↓59.4%	-45↑22.8%	38↑184.7%	11↓70.3%
EPS Diluted	-1.24	-2.58↓108.1%	-2.14↑17.1%	0.62↑129.0%	-0.83↓233.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	330	123↓62.7%	99↓19.6%	120↑21.1%	117↓2.5%
Total Current Assets	354	292↓17.4%	296↑1.1%	360↑21.8%	361↑0.3%
Total Assets	463	447↓3.3%	453↑1.3%	531↑17.2%	579↑8.9%
Total Current Liabilities	25	36↑45.2%	48↑31.9%	49↑3.6%	69↑39.0%
Total Liabilities	51	48↓5.2%	62↑28.8%	75↑21.5%	108↑42.8%
Total Equity	412	399↓3.1%	391↓2.0%	456↑16.5%	471↑3.3%
Total Debt	8	13↑63.4%	15↑14.4%	26↑71.8%	37↑40.1%
Net Debt	-321	-110↑65.9%	-84↑23.8%	-93↓11.8%	-80↑14.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-19	-42↓119.4%	-6↑86.5%	65↑1253.0%	64↓0.8%
Capital Expenditure	-3	-6↓61.7%	-14↓141.9%	-28↓108.0%	-36↓27.2%
Free Cash Flow	-22	-47↓110.5%	-19↑59.3%	37↑289.8%	28↓22.5%
Stock-Based Comp	22	36↑67.1%	51↑41.0%	50↓1.8%	46↓8.8%
Net Change in Cash	-80	-207↓157.7%	-24↑88.3%	21↑186.6%	-3↓114.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance